Pancreas Cancer

Oncology / Haematology

Circulating Tumour DNA Analysis Informing Adjuvant Chemotherapy in Early Stage Pancreatic Cancer: A Multicentre Randomised Study. (Trial Phase 2/3)

Trial Phase

Non-drug Phase 1 Phase 2 Phase 3 Phase 4

Colorectal Cancer

Oncology / Haematology

Circulating Tumour DNA Analysis Informing Adjuvant Chemotherapy in Locally Advanced Rectal Cancer: A Multicentre Randomised Study (DYNAMIC-RECTAL). Randomised multi-centre biomarker-driven adjuvant treatment study. (Trial Phase 2/3)

Trial Phase

Non-drug Phase 1 Phase 2 Phase 3 Phase 4

Colorectal Cancer

Oncology / Haematology

Circulating Tumour DNA Analysis Informing Adjuvant Chemotherapy in Stage III Colon Cancer: A Multicentre Phase II/III Randomised Controlled Study. (Trial Phase 2/3)

Trial Phase

Non-drug Phase 1 Phase 2 Phase 3 Phase 4

Colorectal Cancer

Oncology / Haematology

A randomized, multicenter, parallel-group, Phase III study to compare the efficacy of arfolitixorin versus leucovorin in combination with 5 fluorouracil, oxaliplatin, and bevacizumab in patients with advanced colorectal cancer

Trial Phase

Non-drug Phase 1 Phase 2 Phase 3 Phase 4

Colorectal Cancer

Oncology / Haematology

A Phase 3 Randomized, Open-label Study to Evaluate the Efficacy and Safety of Olaparib Alone or in Combination With Bevacizumab Compared to Bevacizumab with 5-FU in Participants with Unresectable or Metastatic Colorectal Cancer who Have Not Progressed Following First-line Induction of FOLFOX With Bevacizumab

Trial Phase

Non-drug Phase 1 Phase 2 Phase 3 Phase 4

Advanced Solid Tumours

Oncology / Haematology

A Phase I, Open-Label, Multi-Center, Dose Escalation and Expansion Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of IMP4297 in Combination with Temozolomide in Patients with Advanced Solid Tumors and Small Cell Lung Cancer

Trial Phase

Non-drug Phase 1 Phase 2 Phase 3 Phase 4

Prostate Cancer

Oncology / Haematology

A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination with Atezolizumab vs. Second Novel Hormonal Therapy (NHT) in Patients with High Risk, Metastatic Castration-Resistant Prostate Cancer

Trial Phase

Non-drug Phase 1 Phase 2 Phase 3 Phase 4

Urothelial Cancer

Oncology / Haematology

A Phase 3 Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations

Trial Phase

Non-drug Phase 1 Phase 2 Phase 3 Phase 4

Urothelial Cancer

Oncology / Haematology

A Phase 3, Randomized, Double‐blind Study to Compare the Efficacy and Safety of Pembrolizumab (MK‐3475) in Combination with Lenvatinib (E7080) Versus Pembrolizumab and Matching Placebo as First Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma in Cisplatin‐ineligible Participants Whose Tumors Express PD‐L1 and in Any Platinum‐ineligible Participants

Trial Phase

Non-drug Phase 1 Phase 2 Phase 3 Phase 4

Bladder Cancer

Oncology / Haematology

Adding mitomycin to BCG as adjuvant intravesical therapy for high-risk, non–muscle-invasive bladder cancer: a randomised phase 3 trial

Trial Phase

Non-drug Phase 1 Phase 2 Phase 3 Phase 4